Paris, November 20th, 2015 Synerlab pursues its consolidation strategy in Europe Synerlab, a leading pharmaceutical manufacturer, announces today the acquisition of Alcala Farma, a prominent Spanish contract development and manufacturing organization (CDMO). Alcala Farma specializes in the development of proprietary formulation, which represents nearly 40% of its total €M 25…

Pharma Multinationals have struggled to adapt their Romanian strategies, but the local production sector appears to be flourishing. Much of this impetus relates directly to EU accession and the harmonization of manufacturing standards. “Initially, it was difficult to enact the transition, because the authorities handed us strict deadlines to make ourselves…

Romania No one can accuse the Romanian government of being lethargic when it comes to healthcare reform. After an unprecedented seven years of zero new molecules being admitted to the state reimbursement list, the pharma industry has suddenly been subjected to a whirlwind of radical refashioning and legislatory upheaval. “The industry…

Romania Once touted by the IMS as one of the “fast followers” among the world’s “pharmerging” nations and feted by the international investor community in the wake of EU accession, Romania’s pharmaceutical industry appears resurgent once more after a number of years on the back burner. In 2014, Romania’s market size…

CPhI Worldwide 2014, held this year in Paris, was the largest ever event held by the organizers, with more than 36,000 attendees and 2,500 exhibitors. PharmaBoardroom was a media partner of this year’s event, and Frederic Boucheseiche, the founding partner and COO of Focus Reports and PharmaBoardroom, was invited to…

R&D As a result of contractions in the domestic market following the European financial crisis, pharma companies based in Spain have been forced to look elsewhere for business, beyond the borders of Spain and Europe to more far-reaching areas of the globe. Thankfully, the authorities helped out to make this process…

cost containment “Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has brought both benefits and shortcomings. One consequence is that Poland has the lowest average price of medicine in the European…

Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous cost-containment measures, such as increases in co-payments, de-listing hundreds of minor medications and price cuts have all contributed to the…

In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s pharmaceutical market, a tremendous feat considering laws for generics had only been implemented a few years before. Today, generics represent nearly 40 percent of the market in units, with the aim is to increase this…

  When PharmaBoardroom came to Portugal in 2007, price cuts, payment delays and changes to the health system with each successive government were but the first indications for the pharmaceutical sector that troubled times were ahead: four decades of political and financial mismanagement had resulted in Portugal’s economic stagnation. When…

Between Portugal’s two main distribution channels of hospitals and pharmacies, hospitals have suffered in particular. As the pharmaceutical industry’s largest customer, it has been critical for government to work with pharmaceutical companies to find solutions. Robin Turner, general manager of Roche Portugal, likens the relationship of the industry with the…

Basic Research “If you look at the cuts in the public sector, the science budget has been relatively lightly touched. This sends a signal at a very high level that science, the knowledge economy, and the smart training of people are very important for our economic recovery,” says Mark Ferguson, Director General,…